GO:1904401 cellular response to Thyroid stimulating hormone: Signaling Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904401 (cellular response to Thyroid stimulating hormone) describes how a single cell changes its state or activity in response to a Thyroid stimulating hormone (TSH) stimulus, as defined by QuickGO.
• TSH acts through the TSH receptor (TSHR) and downstream cAMP/PKA signaling to alter gene expression, secretion, metabolism and movement in target cells.
• The process is best documented in thyroid follicular cells, but also occurs in extrathyroidal cells such as adipocytes, hepatocytes, cardiomyocytes and immune cells.
• Dysregulation of cellular TSH responses contributes to critical illness thyroid dysfunction, autoimmune thyroiditis, colorectal carcinoma immune evasion, circadian disruption and cardiac arrhythmia.
• Key effector genes include TSHR, CRTC2, TSLP, clock2/npas2 and immune checkpoint genes, which can be modeled with CRISPR knockout, point mutation, knock-in and overexpression.
• Studying GO:1904401 requires integrated methods such as RNA-seq, phosphoproteomics, reporter assays, imaging and CRISPR library screening to resolve cell-type-specific outcomes.
Description
GO:1904401, cellular response to Thyroid stimulating hormone, is a biological process ontology term that captures any change in a cell's state or activity, including movement, secretion, enzyme production and gene expression, that results from a Thyroid stimulating hormone (TSH) stimulus. TSH is the pituitary glycoprotein hormone that classically controls thyroid gland function, but the cellular response to TSH is now recognized as a broader phenomenon affecting multiple tissues and cell types. The term is therefore central to understanding how a single hormonal input is decoded into distinct transcriptional, metabolic and secretory outputs depending on cellular context.
cellular response to Thyroid stimulating hormone At A Glance
| GO ID | GO:1904401 |
|---|---|
| GO term | cellular response to Thyroid stimulating hormone |
| Ontology | biological_process |
| Synonym | none |
| Major function | Transduces a TSH stimulus into changes in cell state or activity, including gene expression, secretion, enzyme production and movement |
| Primary receptor | TSHR (Thyroid stimulating hormone receptor) |
| Major second messenger | cAMP |
| Representative target tissues | Thyroid follicular cells, adipocytes, hepatocytes, cardiomyocytes, immune cells |
| Disease relevance | Critical illness thyroid dysfunction, autoimmune thyroiditis, colorectal carcinoma, circadian disorders, atrial fibrillation |
What Is GO:1904401?
In practical terms, GO:1904401 refers to the intracellular events triggered when TSH binds and activates its receptor on a responsive cell. The QuickGO definition emphasizes that the outcome is a change in cellular state or activity, not merely ligand binding. This includes altered gene expression, secretion, enzyme production and movement. The process is initiated at the plasma membrane by TSHR, propagated by second messengers such as cAMP, and executed by transcription factors, kinases and metabolic enzymes that reprogram the cell.
Why Is cellular response to Thyroid stimulating hormone Important in Cell Biology?
GO:1904401 matters because TSH is not only a thyroid regulator but a pleiotropic hormone whose cellular effects influence metabolism, immunity, cardiac electrophysiology and circadian timing. Understanding this process at the cellular level helps researchers explain why TSH abnormalities associate with diverse clinical phenotypes, from immune evasion in colorectal carcinoma to atrial fibrillation and critical illness thyroid dysfunction. It also provides a framework for designing cell models that dissect which downstream effectors are causal versus correlative.
• Defines how a hormonal stimulus is converted into cell-type-specific transcriptional and metabolic programs.
• Explains extrathyroidal TSH actions in adipocytes, hepatocytes, cardiomyocytes and immune cells.
• Links TSH signaling to hepatic gluconeogenesis through CRTC2, relevant to metabolic disease.
• Connects local TSH/TSHR signaling to CD8+ T cell exhaustion and immune evasion in colorectal carcinoma.
• Provides a mechanistic basis for TSH-associated circadian regulation via clock2/npas2.
• Supports understanding of thyroid dysfunction in critically ill patients.
• Relevant to autoimmune thyroiditis and hypothyroidism management.
• Guides CRISPR-based dissection of TSHR downstream effectors.
• Enables identification of biomarkers for TSH-responsive cancers and cardiac arrhythmia.
• Facilitates drug target discovery for metabolic, immune and cardiovascular indications.
What Happens During cellular response to Thyroid stimulating hormone?
TSH recognition and receptor activation
In simple terms: TSH docks onto its receptor on the cell surface, switching the cell into an alert state.
The cellular response to TSH begins when TSH binds TSHR, a G protein-coupled receptor. This interaction activates Gs proteins and adenylyl cyclase, raising intracellular cAMP. In colorectal carcinoma, local TSH/TSHR signaling promotes CD8+ T cell exhaustion and immune evasion, showing that receptor activation can occur in non-thyroid microenvironments. In cardiomyocytes, thyrotropin directly affects cardiac electrophysiology, indicating that TSHR activation is not restricted to endocrine tissues.
cAMP-dependent signaling and kinase cascades
In simple terms: The receptor signal is amplified inside the cell by messenger molecules and enzymes.
Elevated cAMP activates protein kinase A (PKA) and other effectors that phosphorylate downstream targets. In hepatocytes, TSH increases hepatic gluconeogenesis via CRTC2, a cAMP-responsive coactivator, demonstrating that the cAMP arm of GO:1904401 can reprogram metabolic gene expression. This step converts the initial hormonal signal into a phosphorylation-dependent transcriptional response.
Transcriptional reprogramming
In simple terms: The cell changes which genes are switched on or off.
Activated transcription factors and coactivators alter gene expression programs. TSH-stimulated human adipocytes express thymic stromal lymphopoietin (TSLP), showing that GO:1904401 can induce cytokine-like secreted factors in fat cells. In zebrafish, TSH-thyroid hormone signaling contributes to circadian regulation through repression of clock2/npas2, linking the cellular TSH response to clock gene control.
Secretory and metabolic outputs
In simple terms: The cell releases products or changes its metabolism.
The QuickGO definition explicitly includes secretion and enzyme production. In adipocytes, TSH stimulation drives TSLP secretion. In hepatocytes, TSH promotes gluconeogenic enzyme expression via CRTC2. These outputs illustrate how a single TSH stimulus can produce distinct secretory and metabolic phenotypes depending on cell type.
Cell movement and functional plasticity
In simple terms: The cell may move or change its behavior.
The definition of GO:1904401 includes changes in movement. In the tumor microenvironment, TSH/TSHR signaling influences T cell state and immune evasion, reflecting altered cellular behavior rather than a simple secretory response. In cardiac tissue, TSH effects on electrophysiology represent a functional plasticity outcome of the same ontology term.
Key Genes Involved in GO:1904401 cellular response to Thyroid stimulating hormone
The following genes and proteins are experimentally implicated in the cellular response to Thyroid stimulating hormone (GO:1904401) and its downstream outputs.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TSHR | TSH receptor that initiates the cellular response | Central to all GO:1904401 studies; target for KO and point mutation models |
| CRTC2 | cAMP-responsive coactivator mediating gluconeogenic gene expression | Links TSH to hepatic glucose production; KO and overexpression models |
| TSLP | Secreted cytokine-like factor induced by TSH in adipocytes | Readout of secretory output; overexpression and reporter assays |
| clock2/npas2 | Clock-related gene repressed by TSH-thyroid hormone signaling | Circadian regulation studies; KO and knock-in models |
| CD8+ T cell effector genes | Mediate T cell exhaustion and immune evasion | Tumor immunology; CRISPR screening |
| Cardiac ion channel genes | Determine electrophysiological response to thyrotropin | Atrial fibrillation research; point mutation models |
| Gluconeogenic enzymes (e.g., PCK1, G6PC) | Execute metabolic output of TSH signaling | Metabolic disease models; overexpression and KO |
| PKA catalytic subunits | Phosphorylate downstream targets after cAMP elevation | Signaling dissection; point mutation and KO |
| Adenylyl cyclase isoforms | Produce cAMP upon TSHR activation | Second messenger studies; KO and overexpression |
| Thyroid peroxidase (TPO) | Classical thyroid follicular cell effector | Thyroid function studies; KO models |
| Thyroglobulin (TG) | Thyroid hormone synthesis substrate | Thyroid cell response readout |
| SLC5A5 (NIS) | Iodide transporter in thyroid cells | TSH-responsive thyroid function; overexpression |
| PAX8 | Thyroid transcription factor | Thyroid-specific gene expression; KO and knock-in |
| NKX2-1 | Thyroid transcription factor | Thyroid development and function; KO models |
| FOXE1 | Thyroid transcription factor | Thyroid differentiation; point mutation models |
| Immune checkpoint genes (e.g., PDCD1) | Regulate T cell exhaustion in tumor context | Immuno-oncology; CRISPR KO and screening |
| Circadian clock genes (e.g., arntl, per) | Coordinate circadian output with TSH signaling | Circadian biology; KO and knock-in |
| Myo-inositol pathway genes | Modulate thyroid autoimmunity and hypothyroidism | Autoimmune thyroiditis models; overexpression |
How Is cellular response to Thyroid stimulating hormone Regulated?
The cellular response to TSH is regulated at multiple levels. Receptor availability and desensitization control the magnitude of the initial signal, while cAMP phosphodiesterases and PKA regulatory subunits shape the duration of downstream kinase activity. In hepatocytes, CRTC2 integrates cAMP signals into gluconeogenic gene regulation, providing a node where the response can be tuned. In immune cells, local TSH/TSHR signaling is associated with CD8+ T cell exhaustion, suggesting that the tumor microenvironment can modulate this process. Circadian regulation through clock2/npas2 repression indicates that the response is also temporally gated. In critically ill patients, thyroid function changes reflect systemic regulation of the TSH axis.
cellular response to Thyroid stimulating hormone and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TSHR | Colorectal carcinoma immune evasion | TSHR knockout and overexpression in tumor and T cell lines |
| CRTC2 | Hepatic gluconeogenesis and metabolic disease | CRTC2 knockout and overexpression in hepatocytes |
| TSLP | Adipose tissue inflammation and immune signaling | TSLP reporter knock-in in adipocytes |
| clock2/npas2 | Circadian rhythm disruption | Clock gene knockout and knock-in in zebrafish |
| Cardiac ion channels | Atrial fibrillation | Point mutation knock-in in cardiomyocyte models |
Colorectal carcinoma and immune evasion
Local TSH/TSHR signaling promotes CD8+ T cell exhaustion and immune evasion in colorectal carcinoma, directly linking GO:1904401 to tumor immunology. This suggests that TSH-responsive pathways in immune cells can be therapeutically relevant in colorectal cancer.
Cardiac arrhythmia and atrial fibrillation
Thyrotropin directly affects cardiac electrophysiology and is associated with atrial fibrillation prevalence, indicating that the cellular response to TSH in cardiomyocytes has clinical cardiovascular consequences.
Metabolic and hepatic dysfunction
TSH increases hepatic gluconeogenesis via CRTC2, connecting GO:1904401 to glucose metabolism and potential metabolic disease mechanisms. TSH-stimulated adipocytes express TSLP, further linking the process to adipose tissue biology.
Thyroid autoimmunity and critical illness
Autoimmune thyroiditis and hypothyroidism involve altered TSH responses, and myo-inositol has been studied in this context. In critically ill patients, thyroid function abnormalities reflect dysregulation of the TSH axis and its cellular effects.
From cellular response to Thyroid stimulating hormone-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TSHR mediate the cellular response to TSH in a given cell type? | TSHR knockout cell line |
| Which downstream phosphorylation events are required? | Point mutation knock-in of phospho-null or phospho-mimetic residues |
| How does a disease-associated TSHR variant alter signaling? | Point mutation knock-in of the variant |
| What is the transcriptional output of TSH stimulation? | Tagged knock-in of transcription factors combined with RNA-seq |
| Can overexpression of CRTC2 enhance gluconeogenic output? | CRTC2 overexpression cell model |
| Which genes are essential for TSH-driven immune evasion? | CRISPR library screening in tumor-immune co-culture |
How to Study the cellular response to Thyroid stimulating hormone Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identifying TSH-responsive transcriptional programs |
| Phosphoproteomics | Kinase substrate phosphorylation | Mapping cAMP/PKA downstream events |
| cAMP/PKA activity assay | Second messenger and kinase activity | Confirming TSHR activation |
| Luciferase reporter assay | Promoter activity of target genes | Validating TSH-responsive regulatory elements |
| ELISA | Secreted protein levels | Quantifying TSLP or other secreted factors |
| Live-cell imaging | Cell movement and morphology | Assessing movement-related outputs |
| Electrophysiology | Cardiac electrical activity | Studying thyrotropin effects on cardiomyocytes |
| CRISPR library screening | Gene essentiality in TSH-responsive phenotypes | Identifying immune evasion regulators |
Transcriptomic profiling
RNA-seq after TSH stimulation identifies gene expression changes that define GO:1904401 in a given cell type. This approach has been used to show TSLP induction in adipocytes and clock gene repression in zebrafish.
Phosphoproteomics and signaling assays
Phosphoproteomics and cAMP/PKA activity assays measure the kinase cascades downstream of TSHR activation, including CRTC2-dependent signaling in hepatocytes.
Reporter and secretion assays
Luciferase reporters and ELISA-based secretion assays quantify transcriptional and secretory outputs, such as TSLP release from TSH-stimulated adipocytes.
Imaging and electrophysiology
Live-cell imaging and electrophysiological recordings capture changes in cell movement and cardiac electrical behavior, as shown for thyrotropin effects on cardiomyocytes.
How CRISPR Can Be Used to Study GO:1904401 cellular response to Thyroid stimulating hormone
Knockout
CRISPR knockout of TSHR, CRTC2 or candidate downstream genes can test whether they are required for the cellular response to TSH. For example, TSHR knockout in colorectal carcinoma models can assess effects on CD8+ T cell exhaustion and immune evasion, while CRTC2 knockout in hepatocytes can test gluconeogenic output.
Point Mutation
Point mutation knock-in can model disease-associated variants or phospho-null residues in TSHR, CRTC2 or cardiac ion channels. This is particularly relevant for understanding how thyrotropin affects cardiac electrophysiology and atrial fibrillation risk.
Knock-in
Tagged knock-in of transcription factors or reporters allows real-time monitoring of transcriptional outputs of GO:1904401. Knock-in of clock2/npas2 reporters can reveal circadian regulation by TSH-thyroid hormone signaling.
Overexpression
Overexpression of TSHR, CRTC2 or TSLP can amplify the cellular response to TSH and test sufficiency. CRTC2 overexpression enhances gluconeogenic gene expression in hepatocyte models, and TSLP overexpression can mimic adipocyte secretory output.
How EDITGENE Supports cellular response to Thyroid stimulating hormone Research
Researchers studying cellular response to Thyroid stimulating hormone-related genes often need to determine whether a candidate gene is causally involved in TSH-driven cellular outcomes or merely correlated with them. EDITGENE provides the CRISPR cell models and screening services needed to move from association to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for cellular response to Thyroid stimulating hormone research.
Frequently Asked Questions About cellular response to Thyroid stimulating hormone
What is GO:1904401 cellular response to Thyroid stimulating hormone?
GO:1904401 is a biological process ontology term describing any change in a cell's state or activity, including movement, secretion, enzyme production and gene expression, resulting from a Thyroid stimulating hormone stimulus.
What genes are involved in cellular response to Thyroid stimulating hormone?
Key genes include TSHR, CRTC2, TSLP, clock2/npas2 and immune checkpoint genes, as shown in studies of colorectal carcinoma, hepatocytes, adipocytes and circadian regulation.
How does TSH signal inside a cell?
TSH binds TSHR, activates cAMP/PKA signaling, and alters transcription, secretion and metabolism through effectors such as CRTC2.
Is TSH signaling only in the thyroid?
No. TSH/TSHR signaling has been documented in adipocytes, hepatocytes, cardiomyocytes and immune cells, indicating extrathyroidal cellular responses.
What diseases are linked to cellular response to Thyroid stimulating hormone?
Colorectal carcinoma immune evasion, atrial fibrillation, hepatic gluconeogenesis dysregulation, autoimmune thyroiditis and critical illness thyroid dysfunction have been linked to this process.
How can CRISPR be used to study GO:1904401?
CRISPR knockout, point mutation, knock-in and overexpression can test the requirement and sufficiency of TSHR, CRTC2 and other effectors in TSH-driven cellular outcomes.
What methods measure cellular response to TSH?
RNA-seq, phosphoproteomics, cAMP/PKA assays, reporter assays, ELISA, imaging and electrophysiology are commonly used.
Does TSH affect the immune system?
Local TSH/TSHR signaling promotes CD8+ T cell exhaustion and immune evasion in colorectal carcinoma.
Does TSH influence circadian rhythms?
TSH-thyroid hormone signaling contributes to circadian regulation through repression of clock2/npas2 in zebrafish.
Can TSH affect the heart?
Thyrotropin directly affects cardiac electrophysiology and is associated with atrial fibrillation prevalence.
Conclusion
GO:1904401 cellular response to Thyroid stimulating hormone is a biologically broad process that converts a single hormonal stimulus into cell-type-specific changes in gene expression, secretion, metabolism and movement. Its relevance spans thyroid biology, metabolic disease, cancer immunology, circadian regulation and cardiac electrophysiology. CRISPR-based cell models and integrated omics methods provide a rigorous path to dissect which downstream effectors are causal, enabling new therapeutic hypotheses.
References
- 1. Fliers E et al.. 2015. Thyroid function in critically ill patients.. Lancet Diabetes Endocrinol 3(10):816-25 PMID: 26071885
- 2. Zeng S et al.. 2024. Local TSH/TSHR signaling promotes CD8(+) T cell exhaustion and immune evasion in colorectal carcinoma.. Cancer Commun (Lond) 44(11):1287-1310 PMID: 39285586
- 3. Ji C et al.. 2024. Thyroid-stimulating hormone-thyroid hormone signaling contributes to circadian regulation through repressing clock2/npas2 in zebrafish.. J Genet Genomics 51(1):61-74 PMID: 37328030
- 4. Ma L et al.. 2018. Thyroid-Stimulating Hormone-Stimulated Human Adipocytes Express Thymic Stromal Lymphopoietin.. Horm Metab Res 50(4):325-330 PMID: 29458221
- 6. Rahm AK et al.. 2025. Thyrotropin Directly Affects Cardiac Electrophysiology and Is Associated With AF Prevalence.. Circ Arrhythm Electrophysiol 18(12):e013775 PMID: 41332396
- 7. Li Y et al.. 2017. Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2.. Mol Cell Endocrinol 446:70-80 PMID: 28212844
- 8. Fallahi P et al.. 2018. Myo-inositol in autoimmune thyroiditis, and hypothyroidism.. Rev Endocr Metab Disord 19(4):349-354 PMID: 30506520
